Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2012

Open Access 01-12-2012 | Research article

Relationship between beta-globin gene carrier state and insulin resistance

Authors: Adele Bahar, Zahra Kashi, Mehrnoush Sohrab, Mehrnoush Kosaryan, Ghasem Janbabai

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2012

Login to get access

Abstract

Objective

To assess the relationship between being beta globin gene carrier and developing insulin resistance.

Methods

This study was conducted on 164 subjects including 82 healthy ones and 82 patients with beta thalassemia minor (microcytosis (MCV <80 fl) and hypochromia (MCH <25 pg) and HbA2 ≥ 3.5% using HPLC). Fasting blood glucose (FBS) values of 100–125 mg/dl were considered as impaired fasting glucose, and above 125 mg/dl as diabetes mellitus. Two hours After 75 gram glucose load(GTT), blood sugar level of 140–199 mg/dl was considered as impaired glucose tolerance and above 199 mg/dl as diabetes mellitus. Insulin resistance was diagnosed based on homeostasis model assessment method (HOMA).

Results

According to FBS and BS2hPG values, the percentages of diabetes mellitus, pre diabetes, and normal glucose tolerance in case group was 8.5%, 9.8% and 81.7%, respectively. There was no case of diabetes mellitus in control group and 6.1% of this group were pre diabetic and 93.9% of them had normal glucose tolerance test (P = 0.02). Relative risk for diabetes mellitus and insulin resistance in the cases with minor thalassemia was 2 (95% CI: 1.8-2.5) and 2.02 (95% CI: 1.7-2.4), respectively.

Conclusion

The risk of developing diabetes and insulin resistance in patients with thalassemia minor is two times greater than the general population. Considering the high serum levels of CRP in these cases, the inflammation noted in liver cells could be considered as the underlying cause of insulin resistance, impaired glucose tolerance and diabetes in these patients.
Literature
1.
go back to reference Suvarna J, Ingle H, Deshmukh CT: Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. Indian Pediatr 2006, 43: 393–400. Suvarna J, Ingle H, Deshmukh CT: Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. Indian Pediatr 2006, 43: 393–400.
7.
go back to reference Genuth S, Alberti KG, Bennett P, et al.: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160.CrossRef Genuth S, Alberti KG, Bennett P, et al.: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160.CrossRef
8.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412–9. https://doi.org/10.1007/BF00280883CrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412–9. https://​doi.​org/​10.​1007/​BF00280883CrossRef
11.
go back to reference Burget TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, et al.: Alanine aminotransferase and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrine Metab 2006, 91(11):4287–94. https://doi.org/10.1210/jc.2006-1010CrossRef Burget TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, et al.: Alanine aminotransferase and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrine Metab 2006, 91(11):4287–94. https://​doi.​org/​10.​1210/​jc.​2006-1010CrossRef
12.
go back to reference Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, et al.: Elevated Alanine aminotransferase predicts new onset type 2 Diabetes independently of classical risk factors, metabolic syndrome and C-reactive protein in the West of Scotland coronary prevention study. Diabetes 2004, 53(11):2855–60. https://doi.org/10.2337/diabetes.53.11.2855CrossRef Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, et al.: Elevated Alanine aminotransferase predicts new onset type 2 Diabetes independently of classical risk factors, metabolic syndrome and C-reactive protein in the West of Scotland coronary prevention study. Diabetes 2004, 53(11):2855–60. https://​doi.​org/​10.​2337/​diabetes.​53.​11.​2855CrossRef
16.
go back to reference Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC: Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2011. Epub ahead of print 10.1002/ajh.22223 Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC: Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2011. Epub ahead of print 10.1002/ajh.22223
Metadata
Title
Relationship between beta-globin gene carrier state and insulin resistance
Authors
Adele Bahar
Zahra Kashi
Mehrnoush Sohrab
Mehrnoush Kosaryan
Ghasem Janbabai
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2012
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/2251-6581-11-22

Other articles of this Issue 1/2012

Journal of Diabetes & Metabolic Disorders 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine